Cargando…

Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine

Pancreatic ductal adenocarcinoma (PDAC) is an extremely lethal malignancy, with an average 5-year survival rate of 9% (Siegel RL, Miller KD, Jemal A. Ca Cancer J Clin. 2019;69(1):7-34). The steady increase in mortality rate indicates limited efficacy of the conventional regimen. The heterogeneity of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Yiqi, Yang, Gang, Huang, Hua, Fu, Ziyao, Cao, Zhe, Zheng, Lianfang, You, Lei, Zhang, Taiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783994/ https://www.ncbi.nlm.nih.gov/pubmed/33402215 http://dx.doi.org/10.1186/s13046-020-01787-5

Ejemplares similares

Current epidemiology of pancreatic cancer: Challenges and opportunities
por: Luo, Wenhao, et al.
Publicado: (2020)

Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine
por: Vernuccio, Federica, et al.
Publicado: (2021)

Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
por: Montemagno, Christopher, et al.
Publicado: (2021)

Applied precision medicine in metastatic pancreatic ductal adenocarcinoma
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Recent advances in precision medicine for pancreatic ductal adenocarcinoma
por: Hayashi, Hiromitsu, et al.
Publicado: (2021)

Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine
por: Gerber, Michael H., et al.
Publicado: (2018)

Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities
por: Myo Min, Kay K., et al.
Publicado: (2023)

MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
por: Xiong, Guangbing, et al.
Publicado: (2018)

Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma
por: Xiong, Guangbing, et al.
Publicado: (2021)

Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities
por: Jain, Aditi, et al.
Publicado: (2021)

Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma
por: Rebelo, Rita, et al.
Publicado: (2021)

Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
por: Hoare, Owen, et al.
Publicado: (2021)

Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Therapeutic Opportunities and Clinical Challenges
por: Poh, Ashleigh R., et al.
Publicado: (2021)

Diagnostics and treatment of ovarian cancer in the era of precision medicine - opportunities and challenges
por: Bukłaho, Patrycja Aleksandra, et al.
Publicado: (2023)

Integrated analysis of senescence-associated genes in pancreatic ductal adenocarcinoma
por: Zhu, Zhi-gang, et al.
Publicado: (2022)

Pancreatic Ductal Adenocarcinoma: Preclinical in vitro and ex vivo Models
por: Gündel, Beate, et al.
Publicado: (2021)

Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies
por: Pham, Thao N. D., et al.
Publicado: (2021)

Reconciling evidence-based medicine and precision medicine in the era of big data: challenges and opportunities
por: Beckmann, Jacques S., et al.
Publicado: (2016)

Regulatory role of RNA modifications in the treatment of pancreatic ductal adenocarcinoma (PDAC)
por: Chen, Hao, et al.
Publicado: (2023)

Role of Surgery for Pancreatic Ductal Adenocarcinoma in the Era of Multidisciplinary Treatment
por: Takagi, Kosei, et al.
Publicado: (2023)

Pancreatic cancer: challenges and opportunities
por: Zhu, Huiyun, et al.
Publicado: (2018)

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
por: Hamad, Ahmad, et al.
Publicado: (2021)

Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations
por: Tarabay, Anthony, et al.
Publicado: (2023)

Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress
por: Barcellini, Amelia, et al.
Publicado: (2020)

Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma
por: He, Mengni, et al.
Publicado: (2020)

DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives
por: Stoof, Jojanneke, et al.
Publicado: (2021)

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
por: Luchini, Claudio, et al.
Publicado: (2020)

Challenges and opportunities for precision medicine in neurodevelopmental disorders
por: Chen, George T., et al.
Publicado: (2022)

The personalized medicine for pancreatic ductal adenocarcinoma patients: The oncologist perspective
por: Peretti, Umberto, et al.
Publicado: (2017)

Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications
por: Qiu, Jiangdong, et al.
Publicado: (2018)

Germline Variants in DNA Damage Repair Genes: An Emerging Role in the Era of Precision Medicine in Pancreatic Adenocarcinoma
por: Shoucair, Sami, et al.
Publicado: (2021)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

Models of pancreatic ductal adenocarcinoma
por: Dennaoui, Rayane, et al.
Publicado: (2021)

Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma
por: Trestini, Ilaria, et al.
Publicado: (2021)

Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities
por: Dardare, Julie, et al.
Publicado: (2021)

Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness
por: Seymour, Christopher W., et al.
Publicado: (2017)

Protein Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma: Progress and Challenges
por: Root, Alex, et al.
Publicado: (2018)

The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview
por: Quiñonero, Francisco, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ulleresj3pk67smaolj7hvl0mb